Prelude Therapeutics Incorporated
PRLD
$3.36
$0.061.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M |
| Total Depreciation and Amortization | 418.00K | 425.00K | 433.00K | 435.00K | 489.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.04M | 2.76M | 3.98M | 4.30M | 3.21M |
| Change in Net Operating Assets | 37.12M | -2.57M | 739.00K | -6.88M | 4.29M |
| Cash from Operations | 23.12M | -19.12M | -26.08M | -34.23M | -20.74M |
| Capital Expenditure | 0.00 | 0.00 | -20.00K | -47.00K | -53.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.34M | 40.09M | 11.54M | 62.23M | 22.17M |
| Cash from Investing | -60.34M | 40.09M | 11.52M | 62.19M | 22.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -53.00K | -155.00K | -151.00K |
| Issuance of Common Stock | 24.95M | 0.00 | 92.00K | -- | 124.00K |
| Repurchase of Common Stock | -5.00K | -5.00K | -2.00K | -5.00K | -7.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 24.94M | -5.00K | 37.00K | -160.00K | -34.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.28M | 20.97M | -14.52M | 27.80M | 1.34M |